Clinical trial

A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06487156

StatusACTIVE_NOT_RECRUITING

Study typeOBSERVATIONAL

Start date2023-10-11

PhaseN/A

Study timeline

Study start (actual)2023-10-11Date precision: day

Registry last updated2026-01-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancer (NSCLC)unresolved

Interventions

Nivolumab + ipilimumabDRUG

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

Mapped research locations

NaplesItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06487156 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.